Cardiff Oncology Files 8-K
Ticker: CRDF · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1213037
| Field | Detail |
|---|---|
| Company | Cardiff Oncology, Inc. (CRDF) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC filing, financial-reporting
Related Tickers: CRDF
TL;DR
CRDF filed a routine 8-K, no major news.
AI Summary
Cardiff Oncology, Inc. filed an 8-K on April 8, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for this form type.
Why It Matters
This 8-K filing indicates Cardiff Oncology is fulfilling its reporting obligations with the SEC, which is standard procedure for publicly traded companies.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for reporting financial statements and exhibits, not indicating any new material events or risks.
Key Players & Entities
- Cardiff Oncology, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- San Diego, CA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Cardiff Oncology, Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits, as indicated in the filing details.
On what date was this 8-K report filed?
This 8-K report was filed on April 8, 2024.
What is Cardiff Oncology, Inc.'s principal executive office address?
Cardiff Oncology, Inc.'s principal executive office is located at 11055 Flintkote Avenue, San Diego, CA 92121.
What is Cardiff Oncology, Inc.'s IRS Employer Identification Number?
Cardiff Oncology, Inc.'s IRS Employer Identification Number is 27-2004382.
What is the Commission File Number for Cardiff Oncology, Inc.?
The Commission File Number for Cardiff Oncology, Inc. is 001-35558.
Filing Stats: 548 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2024-04-08 16:07:11
Filing Documents
- crdf-20240408.htm (8-K) — 31KB
- a991ex040824.htm (EX-99.1) — 20KB
- crdf-20240408_g1.jpg (GRAPHIC) — 3KB
- image_0.jpg (GRAPHIC) — 141KB
- 0001628280-24-015247.txt ( ) — 374KB
- crdf-20240408.xsd (EX-101.SCH) — 2KB
- crdf-20240408_lab.xml (EX-101.LAB) — 20KB
- crdf-20240408_pre.xml (EX-101.PRE) — 12KB
- crdf-20240408_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On April 8, 2024, Cardiff Oncology, Inc. issued a press release announcing the presentation of five abstracts at the American Association for Cancer Research (AACR), taking place from April 5-10, 2024, in San Diego, California. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. The information in this report, including the press release furnished as Exhibit 99.1 hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. In addition, the exhibit furnished herewith contain statements intended as "forward-looking statements" that are subject to the cautionary statements about forward-looking statements set forth in such exhibit.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits. 99.1 Press Release of Cardiff Oncology, Inc. dated April 8, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 8, 2024 CARDIFF ONCOLOGY, INC. By: /s/ Mark Erlander Mark Erlander Chief Executive Officer 2